echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > AstraZeneca/Daisankyo's blockbuster ADC for the treatment of non-small cell lung cancer received priority review

    AstraZeneca/Daisankyo's blockbuster ADC for the treatment of non-small cell lung cancer received priority review

    • Last Update: 2022-05-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, AstraZeneca and Daiichi Sankyo jointly announced that the supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan), their jointly developed antibody drug conjugate (ADC), has been granted by the U.
    S.
    FDA for the treatment of patients with unresectable or metastatic non-small cell lung cancer (NSCLC) harboring HER2 mutations

    .
    They had previously received an upfront systemic therapy

    .

    Lung cancer is the second most common type of cancer worldwide, with more than 2 million newly diagnosed patients in 2020
    .
    Patients with metastatic NSCLC have a particularly poor prognosis, with only about 8% of patients living beyond 5 years after diagnosis

    .
    There are currently no approved HER2-targeted therapies for the targeted treatment of NSCLC patients with HER2 mutations

    .

    Enhertu is an ADC therapy jointly developed by AstraZeneca and Daiichi Sankyo
    .
    Designed using Daiichi Sankyo's proprietary DXd ADC technology platform, it consists of a humanized monoclonal antibody targeting HER2 linked to a topoisomerase 1 inhibitor payload via a tetrapeptide cleavable linker

    .
    Enhertu has previously been FDA-approved as a third-line treatment for patients with previously treated HER2-positive unresectable or metastatic HER2-positive breast cancer, as well as HER2-positive locally advanced or metastatic gastric cancer and gastroesophageal junction (GEJ) glands treated with trastuzumab-based therapy cancer patients

    .

    This sBLA is based primarily on positive results from the registrational Phase 2 clinical trial DESTINY-Lung01
    .
    Trial results showed that Enhertu achieved a confirmed objective response rate of 54.
    9% in previously treated NSCLC patients with HER2 mutations

    .
    The disease control rate was 92.
    3%, and tumor shrinkage was observed in the majority of patients

    .

    At a median follow-up of 13.
    1 months, the median duration of response was 9.
    3 months, the median progression-free survival was 8.
    2 months, and the median overall survival was 17.
    8 months

    .
    The results have been published in the New England Journal of Medicine

    .

    Dr Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: "The DESTINY-Lung01 clinical trial validates HER2 gene mutation as a targetable biomarker in non-small cell lung cancer
    .
    If approved, Enhertu has the potential to become a novelty in this patient population.
    potential for standard care

    .
    "

    References:

    [1] Enhertu granted Priority Review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung cancer.
    Retrieved April 19, 2022, from https:// /press-releases/2022/enhertu-granted-priority-review-for-her2m-nsclc.
    html

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.